Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy
- PMID: 30266108
- DOI: 10.24920/21804
Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy
Abstract
Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) is a significant immune checkpoint, and the dysfunction of this axis contributes to tumor metastasis and immune escape. PI3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression. Transcriptional factors such as hypoxia induced factors, PTEN, p53, CDK5, BRD4, STAT modulate PD-1/PD-L1 expression. PD-1/PD-L1 level is also regulated via epigenetic and post-translational manner. The underlying mechanisms mentioned above may provide potential targets for tumor treatment. At present, the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.
Similar articles
-
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.Int J Mol Sci. 2017 Nov 27;18(12):2540. doi: 10.3390/ijms18122540. Int J Mol Sci. 2017. PMID: 29186904 Free PMC article. Review.
-
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.Ann Oncol. 2016 Mar;27(3):409-16. doi: 10.1093/annonc/mdv615. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681673 Review.
-
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.Mol Ther. 2021 Mar 3;29(3):908-919. doi: 10.1016/j.ymthe.2020.12.032. Epub 2021 Jan 1. Mol Ther. 2021. PMID: 33388422 Free PMC article. Review.
-
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.Front Immunol. 2019 Jun 14;10:1337. doi: 10.3389/fimmu.2019.01337. eCollection 2019. Front Immunol. 2019. PMID: 31258527 Free PMC article. Review.
-
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.Front Immunol. 2020 Oct 21;11:568931. doi: 10.3389/fimmu.2020.568931. eCollection 2020. Front Immunol. 2020. PMID: 33193345 Free PMC article. Review.
Cited by
-
Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy.Ann Transl Med. 2021 Oct;9(20):1596. doi: 10.21037/atm-21-4544. Ann Transl Med. 2021. PMID: 34790802 Free PMC article. Review.
-
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.J Immunol Res. 2021 Feb 8;2021:8839978. doi: 10.1155/2021/8839978. eCollection 2021. J Immunol Res. 2021. PMID: 33628854 Free PMC article. Review.
-
Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.Cell Commun Signal. 2022 Jul 27;20(1):114. doi: 10.1186/s12964-022-00909-0. Cell Commun Signal. 2022. PMID: 35897036 Free PMC article. Review.
-
Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion.Int J Mol Sci. 2022 Oct 4;23(19):11789. doi: 10.3390/ijms231911789. Int J Mol Sci. 2022. PMID: 36233088 Free PMC article. Review.
-
Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.Front Oncol. 2022 May 19;12:863392. doi: 10.3389/fonc.2022.863392. eCollection 2022. Front Oncol. 2022. PMID: 35664730 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous